newsfilter
← Latest News
Business Wire·

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

– Sample analysis and data collection ongoing – – Data expected during Q3 2025 – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on